Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada.
The last earnings update was 49 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Xenon Pharmaceuticals. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Xenon Pharmaceuticals's earnings available for a low price, and how does
this compare to other companies in the same industry?
Xenon Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
Xenon Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Xenon Pharmaceuticals's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Xenon Pharmaceuticals's finances.
The net worth of a company is the difference between its assets and liabilities.
Xenon Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Xenon Pharmaceuticals's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Xenon Pharmaceuticals's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Debt is covered by short term assets, assets are 8.1x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Simon N. Pimstone, M.B. ChB., Ph.D., FRCPC, M.D, is a Scientific Co-Founder of Xenon Pharmaceuticals Inc. in 1996 and has been its Chief Executive Officer since January 2003. He had served as President of Xenon Pharmaceuticals Inc. since January 2003 to March 2018 Dr. Pimstone served as the Chief Operating Officer since October 2001 and Vice President, Clinical and Medical Affairs since March 1999 for Xenon Pharmaceuticals Inc. He has served as a consultant physician at the St. Paul’s Hospital Lipid Clinic, Vancouver, BC and an investigator in the Clinical Trials Unit of the Lipid Clinic. He serves as the Chairman of the Providence Healthcare Research Trust. Dr. Pimstone is the author of numerous peer-reviewed publications and book chapters and is also a regular guest speaker at scientific meetings. He served as Clinical Director of the Healthy Heart Society British Columbia Lipid Clinic Outreach Program, a network of lipid clinics serving approximately 4 million people. He is an internal medicine specialist with an interest and expertise in cardiovascular disease. Dr. Pimstone serves as the Chairman of Eupraxia Pharmaceuticals Inc. Dr. Pimstone serves as a Director of Indel Therapeutics Inc. He has been a Director at Xenon Pharmaceuticals Inc. since November 1996 and serves as a Director of BC Biotech. Dr. Pimstone was named in the Globe & Mail’s Canadian Top 40 Under 40 Award. He has extensive training as a clinical and research fellow with the Department of Medical Genetics at the University of British Columbia and obtained his PhD through the University of Amsterdam in cardiovascular genetics. He received his MD from the University of Cape Town where he practiced medicine.
Simon's compensation has increased whilst company is loss making.
Simon's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the Xenon Pharmaceuticals management team is over 5 years, this suggests they are a seasoned and experienced team.
CEO & Director
Executive Vice President of Business & Corporate Development
Senior Vice President of Drug Discovery of Xenon Pharmaceuticals USA Inc
Vice President of Biology
Chief Medical Officer of Xenon Pharmaceuticals USA Inc.
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Xenon Pharmaceuticals board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline include XEN496, A Kv7 potassium channel modulator that is phase II clinical trials for the treatment of KCNQ2 epilepsy; XEN1101, A Kv7 potassium channel modulator, which is in phase II clinical trail for the treatment of epilepsy. The company’s product candidates also comprise XEN901, a selective Nav1.6 sodium channel inhibitor that is in phase I clinical trials for the treatment of epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in phase I clinical trials. The company was founded in 1996 and is headquartered in Burnaby, Canada.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.